ID   KCNB1_RAT               Reviewed;         857 AA.
AC   P15387;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2002, sequence version 3.
DT   24-JUL-2024, entry version 188.
DE   RecName: Full=Potassium voltage-gated channel subfamily B member 1 {ECO:0000250|UniProtKB:Q14721};
DE   AltName: Full=Delayed rectifier potassium channel 1 {ECO:0000303|PubMed:2770868};
DE            Short=DRK1 {ECO:0000303|PubMed:2770868};
DE   AltName: Full=Voltage-gated potassium channel subunit Kv2.1;
GN   Name=Kcnb1 {ECO:0000312|RGD:2954};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-857, FUNCTION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY REGULATION.
RC   TISSUE=Brain;
RX   PubMed=2770868; DOI=10.1038/340642a0;
RA   Frech G.C., Vandongen A.M.J., Schuster G., Brown A.M., Joho R.H.;
RT   "A novel potassium channel with delayed rectifier properties isolated from
RT   rat brain by expression cloning.";
RL   Nature 340:642-645(1989).
RN   [2]
RP   SEQUENCE REVISION.
RA   Frech G.C.;
RL   Submitted (FEB-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-575, AND TISSUE SPECIFICITY.
RX   PubMed=1740690; DOI=10.1523/jneurosci.12-02-00538.1992;
RA   Drewe J.A., Verma S., Frech G.C., Joho R.H.;
RT   "Distinct spatial and temporal expression patterns of K+ channel mRNAs from
RT   different subfamilies.";
RL   J. Neurosci. 12:538-548(1992).
RN   [4]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=2206531; DOI=10.1016/0896-6273(90)90082-q;
RA   VanDongen A.M., Frech G.C., Drewe J.A., Joho R.H., Brown A.M.;
RT   "Alteration and restoration of K+ channel function by deletions at the
RT   N- and C-termini.";
RL   Neuron 5:433-443(1990).
RN   [5]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=1875913;
RA   Taglialatela M., Vandongen A.M., Drewe J.A., Joho R.H., Brown A.M.,
RA   Kirsch G.E.;
RT   "Patterns of internal and external tetraethylammonium block in four
RT   homologous K+ channels.";
RL   Mol. Pharmacol. 40:299-307(1991).
RN   [6]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=1961744; DOI=10.1073/pnas.88.23.10764;
RA   Trimmer J.S.;
RT   "Immunological identification and characterization of a delayed rectifier
RT   K+ channel polypeptide in rat brain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10764-10768(1991).
RN   [7]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8508921; DOI=10.1016/0014-5793(93)81394-f;
RA   Trimmer J.S.;
RT   "Expression of Kv2.1 delayed rectifier K+ channel isoforms in the
RT   developing rat brain.";
RL   FEBS Lett. 324:205-210(1993).
RN   [8]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8463836; DOI=10.1523/jneurosci.13-04-01569.1993;
RA   Hwang P.M., Fotuhi M., Bredt D.S., Cunningham A.M., Snyder S.H.;
RT   "Contrasting immunohistochemical localizations in rat brain of two novel K+
RT   channels of the Shab subfamily.";
RL   J. Neurosci. 13:1569-1576(1993).
RN   [9]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   PHOSPHORYLATION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND LACK OF
RP   GLYCOSYLATION.
RX   PubMed=8083226; DOI=10.1016/s0021-9258(17)31640-x;
RA   Shi G., Kleinklaus A.K., Marrion N.V., Trimmer J.S.;
RT   "Properties of Kv2.1 K+ channels expressed in transfected mammalian
RT   cells.";
RL   J. Biol. Chem. 269:23204-23211(1994).
RN   [10]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND LACK OF INTERACTION WITH
RP   KCNAB1 AND KCNAB2.
RX   PubMed=7623158; DOI=10.1523/jneurosci.15-07-05360.1995;
RA   Rhodes K.J., Keilbaugh S.A., Barrezueta N.X., Lopez K.L., Trimmer J.S.;
RT   "Association and colocalization of K+ channel alpha- and beta-subunit
RT   polypeptides in rat brain.";
RL   J. Neurosci. 15:5360-5371(1995).
RN   [11]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=7576642; DOI=10.1016/0896-6273(95)90184-1;
RA   Swartz K.J., MacKinnon R.;
RT   "An inhibitor of the Kv2.1 potassium channel isolated from the venom of a
RT   Chilean tarantula.";
RL   Neuron 15:941-949(1995).
RN   [12]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=8978827; DOI=10.1083/jcb.135.6.1619;
RA   Scannevin R.H., Murakoshi H., Rhodes K.J., Trimmer J.S.;
RT   "Identification of a cytoplasmic domain important in the polarized
RT   expression and clustering of the Kv2.1 K+ channel.";
RL   J. Cell Biol. 135:1619-1632(1996).
RN   [13]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNV1, AND SUBCELLULAR LOCATION.
RX   PubMed=8670833; DOI=10.1002/j.1460-2075.1996.tb00697.x;
RA   Hugnot J.-P., Salinas M., Lesage F., Guillemare E., de Weille J.,
RA   Heurteaux C., Mattei M.-G., Lazdunski M.;
RT   "Kv8.1, a new neuronal potassium channel subunit with specific inhibitory
RT   properties towards Shab and Shaw channels.";
RL   EMBO J. 15:3322-3331(1996).
RN   [14]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNG1, AND SUBCELLULAR LOCATION.
RX   PubMed=8980147; DOI=10.1016/s0014-5793(96)01316-6;
RA   Post M.A., Kirsch G.E., Brown A.M.;
RT   "Kv2.1 and electrically silent Kv6.1 potassium channel subunits combine and
RT   express a novel current.";
RL   FEBS Lett. 399:177-182(1996).
RN   [15]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBUNIT, INTERACTION WITH KCNS3,
RP   SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=9362476; DOI=10.1093/emboj/16.22.6615;
RA   Patel A.J., Lazdunski M., Honore E.;
RT   "Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-
RT   sensitive pulmonary artery myocytes.";
RL   EMBO J. 16:6615-6625(1997).
RN   [16]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=9079713; DOI=10.1074/jbc.272.13.8774;
RA   Salinas M., de Weille J., Guillemare E., Lazdunski M., Hugnot J.-P.;
RT   "Modes of regulation of shab K+ channel activity by the Kv8.1 subunit.";
RL   J. Biol. Chem. 272:8774-8780(1997).
RN   [17]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=9305895; DOI=10.1074/jbc.272.39.24371;
RA   Salinas M., Duprat F., Heurteaux C., Hugnot J.-P., Lazdunski M.;
RT   "New modulatory alpha subunits for mammalian Shab K+ channels.";
RL   J. Biol. Chem. 272:24371-24379(1997).
RN   [18]
RP   FUNCTION, TRANSPORTER ACTIVITY, PHOSPHORYLATION, AND MUTAGENESIS OF SER-444
RP   AND SER-496.
RX   PubMed=9351973; DOI=10.1124/mol.52.5.821;
RA   Murakoshi H., Shi G., Scannevin R.H., Trimmer J.S.;
RT   "Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent
RT   activation.";
RL   Mol. Pharmacol. 52:821-828(1997).
RN   [19]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNF1 AND KCNG1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=9696692; DOI=10.1152/ajpcell.1998.274.6.c1501;
RA   Kramer J.W., Post M.A., Brown A.M., Kirsch G.E.;
RT   "Modulation of potassium channel gating by coexpression of Kv2.1 with
RT   regulatory Kv5.1 or Kv6.1 alpha-subunits.";
RL   Am. J. Physiol. 274:C1501-C1510(1998).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9616203; DOI=10.1172/jci333;
RA   Archer S.L., Souil E., Dinh-Xuan A.T., Schremmer B., Mercier J.C.,
RA   El Yaagoubi A., Nguyen-Huu L., Reeve H.L., Hampl V.;
RT   "Molecular identification of the role of voltage-gated K+ channels, Kv1.5
RT   and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting
RT   membrane potential in rat pulmonary artery myocytes.";
RL   J. Clin. Invest. 101:2319-2330(1998).
RN   [21]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   INTERACTION WITH PIAS3.
RX   PubMed=9565597; DOI=10.1074/jbc.273.19.11745;
RA   Wible B.A., Yang Q., Kuryshev Y.A., Accili E.A., Brown A.M.;
RT   "Cloning and expression of a novel K+ channel regulatory protein, KChAP.";
RL   J. Biol. Chem. 273:11745-11751(1998).
RN   [22]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9522360; DOI=10.1016/s0306-4522(97)00519-8;
RA   Du J., Tao-Cheng J.H., Zerfas P., McBain C.J.;
RT   "The K+ channel, Kv2.1, is apposed to astrocytic processes and is
RT   associated with inhibitory postsynaptic membranes in hippocampal and
RT   cortical principal neurons and inhibitory interneurons.";
RL   Neuroscience 84:37-48(1998).
RN   [23]
RP   REVIEW.
RX   PubMed=10414301; DOI=10.1111/j.1749-6632.1999.tb11293.x;
RA   Coetzee W.A., Amarillo Y., Chiu J., Chow A., Lau D., McCormack T.,
RA   Moreno H., Nadal M.S., Ozaita A., Pountney D., Saganich M.,
RA   Vega-Saenz de Miera E., Rudy B.;
RT   "Molecular diversity of K+ channels.";
RL   Ann. N. Y. Acad. Sci. 868:233-285(1999).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10024359; DOI=10.1523/jneurosci.19-05-01728.1999;
RA   Murakoshi H., Trimmer J.S.;
RT   "Identification of the Kv2.1 K+ channel as a major component of the delayed
RT   rectifier K+ current in rat hippocampal neurons.";
RL   J. Neurosci. 19:1728-1735(1999).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10414968; DOI=10.1523/jneurosci.19-15-06394.1999;
RA   Baranauskas G., Tkatch T., Surmeier D.J.;
RT   "Delayed rectifier currents in rat globus pallidus neurons are attributable
RT   to Kv2.1 and Kv3.1/3.2 K(+) channels.";
RL   J. Neurosci. 19:6394-6404(1999).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10618149; DOI=10.1111/j.1469-7793.2000.t01-2-00019.xm;
RA   Du J., Haak L.L., Phillips-Tansey E., Russell J.T., McBain C.J.;
RT   "Frequency-dependent regulation of rat hippocampal somato-dendritic
RT   excitability by the K+ channel subunit Kv2.1.";
RL   J. Physiol. (Lond.) 522:19-31(2000).
RN   [27]
RP   SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF SER-587; SER-590; PHE-591
RP   AND SER-593.
RX   PubMed=10719893; DOI=10.1016/s0896-6273(00)80902-2;
RA   Lim S.T., Antonucci D.E., Scannevin R.H., Trimmer J.S.;
RT   "A novel targeting signal for proximal clustering of the Kv2.1 K+ channel
RT   in hippocampal neurons.";
RL   Neuron 25:385-397(2000).
RN   [28]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11463864; DOI=10.1210/mend.15.8.0685;
RA   MacDonald P.E., Ha X.F., Wang J., Smukler S.R., Sun A.M., Gaisano H.Y.,
RA   Salapatek A.M., Backx P.H., Wheeler M.B.;
RT   "Members of the Kv1 and Kv2 voltage-dependent K(+) channel families
RT   regulate insulin secretion.";
RL   Mol. Endocrinol. 15:1423-1435(2001).
RN   [29]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   TRP-369 AND TYR-384.
RX   PubMed=12451110; DOI=10.1523/jneurosci.22-23-10094.2002;
RA   Malin S.A., Nerbonne J.M.;
RT   "Delayed rectifier K+ currents, IK, are encoded by Kv2 alpha-subunits and
RT   regulate tonic firing in mammalian sympathetic neurons.";
RL   J. Neurosci. 22:10094-10105(2002).
RN   [30]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12127166; DOI=10.1016/s0024-3205(02)01922-7;
RA   Lu Y., Hanna S.T., Tang G., Wang R.;
RT   "Contributions of Kv1.2, Kv1.5 and Kv2.1 subunits to the native delayed
RT   rectifier K(+) current in rat mesenteric artery smooth muscle cells.";
RL   Life Sci. 71:1465-1473(2002).
RN   [31]
RP   FUNCTION, INTERACTION WITH SNAP25, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12403834; DOI=10.1210/me.2002-0058;
RA   MacDonald P.E., Wang G., Tsuk S., Dodo C., Kang Y., Tang L., Wheeler M.B.,
RA   Cattral M.S., Lakey J.R., Salapatek A.M., Lotan I., Gaisano H.Y.;
RT   "Synaptosome-associated protein of 25 kilodaltons modulates Kv2.1 voltage-
RT   dependent K(+) channels in neuroendocrine islet beta-cells through an
RT   interaction with the channel N terminus.";
RL   Mol. Endocrinol. 16:2452-2461(2002).
RN   [32]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=12065754; DOI=10.1124/mol.62.1.48;
RA   Escoubas P., Diochot S., Celerier M.-L., Nakajima T., Lazdunski M.;
RT   "Novel tarantula toxins for subtypes of voltage-dependent potassium
RT   channels in the Kv2 and Kv4 subfamilies.";
RL   Mol. Pharmacol. 62:48-57(2002).
RN   [33]
RP   FUNCTION, TRANSPORTER ACTIVITY, SELF-ASSOCIATION, DOMAIN, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF GLN-71 AND GLU-79.
RX   PubMed=12560340; DOI=10.1074/jbc.m212973200;
RA   Ju M., Stevens L., Leadbitter E., Wray D.;
RT   "The Roles of N- and C-terminal determinants in the activation of the Kv2.1
RT   potassium channel.";
RL   J. Biol. Chem. 278:12769-12778(2003).
RN   [34]
RP   PHOSPHORYLATION AT TYR-128, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TYR-128.
RX   PubMed=12615930; DOI=10.1074/jbc.m212766200;
RA   Tiran Z., Peretz A., Attali B., Elson A.;
RT   "Phosphorylation-dependent regulation of Kv2.1 Channel activity at tyrosine
RT   124 by Src and by protein-tyrosine phosphatase epsilon.";
RL   J. Biol. Chem. 278:17509-17514(2003).
RN   [35]
RP   FUNCTION, INTERACTION WITH STX1A, AND SUBCELLULAR LOCATION.
RX   PubMed=12621036; DOI=10.1074/jbc.m213088200;
RA   Leung Y.M., Kang Y., Gao X., Xia F., Xie H., Sheu L., Tsuk S., Lotan I.,
RA   Tsushima R.G., Gaisano H.Y.;
RT   "Syntaxin 1A binds to the cytoplasmic C terminus of Kv2.1 to regulate
RT   channel gating and trafficking.";
RL   J. Biol. Chem. 278:17532-17538(2003).
RN   [36]
RP   FUNCTION, INTERACTION WITH SNP25 AND STX1A, AND SUBCELLULAR LOCATION.
RX   PubMed=12807875; DOI=10.1074/jbc.m304943200;
RA   Michaelevski I., Chikvashvili D., Tsuk S., Singer-Lahat D., Kang Y.,
RA   Linial M., Gaisano H.Y., Fili O., Lotan I.;
RT   "Direct interaction of target SNAREs with the Kv2.1 channel. Modal
RT   regulation of channel activation and inactivation gating.";
RL   J. Biol. Chem. 278:34320-34330(2003).
RN   [37]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   TRP-369 AND TYR-384.
RX   PubMed=12832499; DOI=10.1523/jneurosci.23-12-04798.2003;
RA   Pal S., Hartnett K.A., Nerbonne J.M., Levitan E.S., Aizenman E.;
RT   "Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels.";
RL   J. Neurosci. 23:4798-4802(2003).
RN   [38]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNE3, SUBCELLULAR LOCATION, DOMAIN,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=12954870; DOI=10.1523/jneurosci.23-22-08077.2003;
RA   McCrossan Z.A., Lewis A., Panaghie G., Jordan P.N., Christini D.J.,
RA   Lerner D.J., Abbott G.W.;
RT   "MinK-related peptide 2 modulates Kv2.1 and Kv3.1 potassium channels in
RT   mammalian brain.";
RL   J. Neurosci. 23:8077-8091(2003).
RN   [39]
RP   FUNCTION, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15322114; DOI=10.1074/jbc.m408789200;
RA   Amberg G.C., Rossow C.F., Navedo M.F., Santana L.F.;
RT   "NFATc3 regulates Kv2.1 expression in arterial smooth muscle.";
RL   J. Biol. Chem. 279:47326-47334(2004).
RN   [40]
RP   FUNCTION, PHOSPHORYLATION, DEPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=15195093; DOI=10.1038/nn1260;
RA   Misonou H., Mohapatra D.P., Park E.W., Leung V., Zhen D., Misonou K.,
RA   Anderson A.E., Trimmer J.S.;
RT   "Regulation of ion channel localization and phosphorylation by neuronal
RT   activity.";
RL   Nat. Neurosci. 7:711-718(2004).
RN   [41]
RP   REVIEW.
RX   PubMed=15858231; DOI=10.1385/cbb:42:2:167;
RA   Cox R.H.;
RT   "Molecular determinants of voltage-gated potassium currents in vascular
RT   smooth muscle.";
RL   Cell Biochem. Biophys. 42:167-195(2005).
RN   [42]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15855232; DOI=10.1242/jcs.02348;
RA   O'Connell K.M., Tamkun M.M.;
RT   "Targeting of voltage-gated potassium channel isoforms to distinct cell
RT   surface microdomains.";
RL   J. Cell Sci. 118:2155-2166(2005).
RN   [43]
RP   FUNCTION, PHOSPHORYLATION, DEPHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=16319318; DOI=10.1523/jneurosci.3370-05.2005;
RA   Misonou H., Mohapatra D.P., Menegola M., Trimmer J.S.;
RT   "Calcium- and metabolic state-dependent modulation of the voltage-dependent
RT   Kv2.1 channel regulates neuronal excitability in response to ischemia.";
RL   J. Neurosci. 25:11184-11193(2005).
RN   [44]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16273079; DOI=10.1038/sj.cdd.4401792;
RA   Pal S.K., Takimoto K., Aizenman E., Levitan E.S.;
RT   "Apoptotic surface delivery of K+ channels.";
RL   Cell Death Differ. 13:661-667(2006).
RN   [45]
RP   FUNCTION, PHOSPHORYLATION, DEPHOSPHORYLATION, DOMAIN, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16407566; DOI=10.1523/jneurosci.4620-05.2006;
RA   Mohapatra D.P., Trimmer J.S.;
RT   "The Kv2.1 C terminus can autonomously transfer Kv2.1-like phosphorylation-
RT   dependent localization, voltage-dependent gating, and muscarinic modulation
RT   to diverse Kv channels.";
RL   J. Neurosci. 26:685-695(2006).
RN   [46]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16988031; DOI=10.1523/jneurosci.1825-06.2006;
RA   O'Connell K.M., Rolig A.S., Whitesell J.D., Tamkun M.M.;
RT   "Kv2.1 potassium channels are retained within dynamic cell surface
RT   microdomains that are defined by a perimeter fence.";
RL   J. Neurosci. 26:9609-9618(2006).
RN   [47]
RP   PHOSPHORYLATION AT SER-457; SER-567; SER-607 AND SER-719, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND FUNCTION.
RX   PubMed=17192433; DOI=10.1523/jneurosci.3970-06.2006;
RA   Misonou H., Menegola M., Mohapatra D.P., Guy L.K., Park K.-S.,
RA   Trimmer J.S.;
RT   "Bidirectional activity-dependent regulation of neuronal ion channel
RT   phosphorylation.";
RL   J. Neurosci. 26:13505-13514(2006).
RN   [48]
RP   PHOSPHORYLATION AT SER-15; SER-457; SER-484; SER-496; SER-503; SER-520;
RP   SER-541; SER-567; SER-590; SER-607; SER-655; SER-719; SER-771; SER-799;
RP   SER-804 AND THR-836, FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   MUTAGENESIS OF SER-15; SER-457; SER-484; SER-541; SER-567; SER-607;
RP   SER-655; SER-719; SER-771 AND SER-804.
RX   PubMed=16917065; DOI=10.1126/science.1124254;
RA   Park K.-S., Mohapatra D.P., Misonou H., Trimmer J.S.;
RT   "Graded regulation of the Kv2.1 potassium channel by variable
RT   phosphorylation.";
RL   Science 313:976-979(2006).
RN   [49]
RP   PHOSPHORYLATION AT SER-15; SER-457; SER-541; SER-607; SER-655; SER-719;
RP   SER-799; SER-804 AND THR-836, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18690023; DOI=10.4161/chan.4388;
RA   Park K.S., Mohapatra D.P., Trimmer J.S.;
RT   "Proteomic analyses of K(v)2.1 channel phosphorylation sites determining
RT   cell background specific differences in function.";
RL   Channels 1:59-61(2007).
RN   [50]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17606996; DOI=10.1242/jcs.007351;
RA   Tamkun M.M., O'connell K.M., Rolig A.S.;
RT   "A cytoskeletal-based perimeter fence selectively corrals a sub-population
RT   of cell surface Kv2.1 channels.";
RL   J. Cell Sci. 120:2413-2423(2007).
RN   [51]
RP   FUNCTION, INTERACTION WITH STX1A, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TRP-369 AND TYR-384.
RX   PubMed=17301173; DOI=10.1523/jneurosci.4006-06.2007;
RA   Singer-Lahat D., Sheinin A., Chikvashvili D., Tsuk S., Greitzer D.,
RA   Friedrich R., Feinshreiber L., Ashery U., Benveniste M., Levitan E.S.,
RA   Lotan I.;
RT   "K+ channel facilitation of exocytosis by dynamic interaction with
RT   syntaxin.";
RL   J. Neurosci. 27:1651-1658(2007).
RN   [52]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17379638; DOI=10.1113/jphysiol.2007.128454;
RA   Guan D., Tkatch T., Surmeier D.J., Armstrong W.E., Foehring R.C.;
RT   "Kv2 subunits underlie slowly inactivating potassium current in rat
RT   neocortical pyramidal neurons.";
RL   J. Physiol. (Lond.) 581:941-960(2007).
RN   [53]
RP   PHOSPHORYLATION AT SER-804, MUTAGENESIS OF TRP-369; TYR-384 AND SER-804,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17360683; DOI=10.1073/pnas.0610159104;
RA   Redman P.T., He K., Hartnett K.A., Jefferson B.S., Hu L., Rosenberg P.A.,
RA   Levitan E.S., Aizenman E.;
RT   "Apoptotic surge of potassium currents is mediated by p38 phosphorylation
RT   of Kv2.1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3568-3573(2007).
RN   [54]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17965280; DOI=10.1152/ajpheart.01038.2007;
RA   O'Connell K.M., Whitesell J.D., Tamkun M.M.;
RT   "Localization and mobility of the delayed-rectifer K+ channel Kv2.1 in
RT   adult cardiomyocytes.";
RL   Am. J. Physiol. 294:H229-H237(2008).
RN   [55]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19014551; DOI=10.1186/1471-2202-9-112;
RA   Sarmiere P.D., Weigle C.M., Tamkun M.M.;
RT   "The Kv2.1 K+ channel targets to the axon initial segment of hippocampal
RT   and cortical neurons in culture and in situ.";
RL   BMC Neurosci. 9:112-112(2008).
RN   [56]
RP   FUNCTION, SELF-ASSOCIATION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND
RP   DOMAIN.
RX   PubMed=18463252; DOI=10.1523/jneurosci.0186-08.2008;
RA   Mohapatra D.P., Siino D.F., Trimmer J.S.;
RT   "Interdomain cytoplasmic interactions govern the intracellular trafficking,
RT   gating, and modulation of the Kv2.1 channel.";
RL   J. Neurosci. 28:4982-4994(2008).
RN   [57]
RP   INTERACTION WITH VAMP2, AND SUBCELLULAR LOCATION.
RX   PubMed=18542995; DOI=10.1007/s00424-008-0468-7;
RA   Lvov A., Chikvashvili D., Michaelevski I., Lotan I.;
RT   "VAMP2 interacts directly with the N terminus of Kv2.1 to enhance channel
RT   inactivation.";
RL   Pflugers Arch. 456:1121-1136(2008).
RN   [58]
RP   FUNCTION, INTERACTION WITH STX1A, AND SUBCELLULAR LOCATION.
RX   PubMed=18167541; DOI=10.1371/journal.pone.0001381;
RA   Singer-Lahat D., Chikvashvili D., Lotan I.;
RT   "Direct interaction of endogenous Kv channels with syntaxin enhances
RT   exocytosis by neuroendocrine cells.";
RL   PLoS ONE 3:E1381-E1381(2008).
RN   [59]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19276663; DOI=10.4161/chan.3.1.7655;
RA   Mohapatra D.P., Misonou H., Pan S.J., Held J.E., Surmeier D.J.,
RA   Trimmer J.S.;
RT   "Regulation of intrinsic excitability in hippocampal neurons by activity-
RT   dependent modulation of the KV2.1 potassium channel.";
RL   Channels 3:46-56(2009).
RN   [60]
RP   TISSUE SPECIFICITY.
RX   PubMed=19074135; DOI=10.1074/jbc.m808786200;
RA   Mederos y Schnitzler M., Rinne S., Skrobek L., Renigunta V.,
RA   Schlichthorl G., Derst C., Gudermann T., Daut J., Preisig-Muller R.;
RT   "Mutation of histidine 105 in the T1 domain of the potassium channel Kv2.1
RT   disrupts heteromerization with Kv6.3 and Kv6.4.";
RL   J. Biol. Chem. 284:4695-4704(2009).
RN   [61]
RP   INTERACTION WITH VAMP2, SELF-ASSOCIATION, DOMAIN, AND SUBCELLULAR LOCATION.
RX   PubMed=19690160; DOI=10.1074/jbc.m109.028761;
RA   Lvov A., Greitzer D., Berlin S., Chikvashvili D., Tsuk S., Lotan I.,
RA   Michaelevski I.;
RT   "Rearrangements in the relative orientation of cytoplasmic domains induced
RT   by a membrane-anchored protein mediate modulations in Kv channel gating.";
RL   J. Biol. Chem. 284:28276-28291(2009).
RN   [62]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNE1 AND KCNE2, SUBCELLULAR LOCATION,
RP   DOMAIN, AND TISSUE SPECIFICITY.
RX   PubMed=19219384; DOI=10.1007/s00232-009-9154-8;
RA   McCrossan Z.A., Roepke T.K., Lewis A., Panaghie G., Abbott G.W.;
RT   "Regulation of the Kv2.1 potassium channel by MinK and MiRP1.";
RL   J. Membr. Biol. 228:1-14(2009).
RN   [63]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SNAP25; STX1A AND
RP   VAMP2.
RX   PubMed=19077057; DOI=10.1111/j.1471-4159.2008.05834.x;
RA   Yao H., Zhou K., Yan D., Li M., Wang Y.;
RT   "The Kv2.1 channels mediate neuronal apoptosis induced by excitotoxicity.";
RL   J. Neurochem. 108:909-919(2009).
RN   [64]
RP   FUNCTION, PHOSPHORYLATION AT TYR-128, DEPHOSPHORYLATION, AND MUTAGENESIS OF
RP   TYR-128 AND SER-804.
RX   PubMed=19622611; DOI=10.1113/jphysiol.2009.176321;
RA   Redman P.T., Hartnett K.A., Aras M.A., Levitan E.S., Aizenman E.;
RT   "Regulation of apoptotic potassium currents by coordinated zinc-dependent
RT   signalling.";
RL   J. Physiol. (Lond.) 587:4393-4404(2009).
RN   [65]
RP   FUNCTION, SUBUNIT, INTERACTION WITH KCNB2, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF TRP-369 AND TYR-384, TISSUE SPECIFICITY, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=20202934; DOI=10.1074/jbc.m109.074260;
RA   Kihira Y., Hermanstyne T.O., Misonou H.;
RT   "Formation of heteromeric Kv2 channels in mammalian brain neurons.";
RL   J. Biol. Chem. 285:15048-15055(2010).
RN   [66]
RP   FUNCTION, INTERACTION WITH STX1A, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TRP-369 AND TYR-384.
RX   PubMed=20484665; DOI=10.1242/jcs.063719;
RA   Feinshreiber L., Singer-Lahat D., Friedrich R., Matti U., Sheinin A.,
RA   Yizhar O., Nachman R., Chikvashvili D., Rettig J., Ashery U., Lotan I.;
RT   "Non-conducting function of the Kv2.1 channel enables it to recruit
RT   vesicles for release in neuroendocrine and nerve cells.";
RL   J. Cell Sci. 123:1940-1947(2010).
RN   [67]
RP   PHOSPHORYLATION AT SER-520; SER-655; SER-607 AND SER-804, DEPHOSPHORYLATION
RP   AT SER-607, AND SUBCELLULAR LOCATION.
RX   PubMed=21712386; DOI=10.1074/jbc.m111.251942;
RA   Cerda O., Trimmer J.S.;
RT   "Activity-dependent phosphorylation of neuronal Kv2.1 potassium channels by
RT   CDK5.";
RL   J. Biol. Chem. 286:28738-28748(2011).
RN   [68]
RP   FUNCTION, SUMOYLATION AT LYS-474, DESUMOYLATION, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF LYS-149; LYS-259 AND LYS-474, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=21518833; DOI=10.1085/jgp.201110604;
RA   Plant L.D., Dowdell E.J., Dementieva I.S., Marks J.D., Goldstein S.A.;
RT   "SUMO modification of cell surface Kv2.1 potassium channels regulates the
RT   activity of rat hippocampal neurons.";
RL   J. Gen. Physiol. 137:441-454(2011).
RN   [69]
RP   PHOSPHORYLATION, ACETYLATION, AND INTERACTION WITH CREB1.
RX   PubMed=21818121; DOI=10.1038/cdd.2011.102;
RA   Kim S.J., Widenmaier S.B., Choi W.S., Nian C., Ao Z., Warnock G.,
RA   McIntosh C.H.;
RT   "Pancreatic beta-cell prosurvival effects of the incretin hormones involve
RT   post-translational modification of Kv2.1 delayed rectifier channels.";
RL   Cell Death Differ. 19:333-344(2012).
RN   [70]
RP   FUNCTION, INTERACTION WITH STX1A, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   AND MUTAGENESIS OF TRP-369 AND TYR-384.
RX   PubMed=22411134; DOI=10.1007/s00125-012-2512-6;
RA   Dai X.Q., Manning Fox J.E., Chikvashvili D., Casimir M., Plummer G.,
RA   Hajmrle C., Spigelman A.F., Kin T., Singer-Lahat D., Kang Y., Shapiro A.M.,
RA   Gaisano H.Y., Lotan I., Macdonald P.E.;
RT   "The voltage-dependent potassium channel subunit Kv2.1 regulates insulin
RT   secretion from rodent and human islets independently of its electrical
RT   function.";
RL   Diabetologia 55:1709-1720(2012).
RN   [71]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22648171; DOI=10.1091/mbc.e12-01-0047;
RA   Deutsch E., Weigel A.V., Akin E.J., Fox P., Hansen G., Haberkorn C.J.,
RA   Loftus R., Krapf D., Tamkun M.M.;
RT   "Kv2.1 cell surface clusters are insertion platforms for ion channel
RT   delivery to the plasma membrane.";
RL   Mol. Biol. Cell 23:2917-2929(2012).
RN   [72]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-484; SER-519; SER-520 AND
RP   SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [73]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23878373; DOI=10.1113/jphysiol.2013.257253;
RA   Guan D., Armstrong W.E., Foehring R.C.;
RT   "Kv2 channels regulate firing rate in pyramidal neurons from rat
RT   sensorimotor cortex.";
RL   J. Physiol. (Lond.) 591:4807-4825(2013).
RN   [74]
RP   INTERACTION WITH MYL12B, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-590.
RX   PubMed=24569993; DOI=10.1074/jbc.m113.534495;
RA   Jensen C.S., Watanabe S., Rasmussen H.B., Schmitt N., Olesen S.P.,
RA   Frost N.A., Blanpied T.A., Misonou H.;
RT   "Specific sorting and post-Golgi trafficking of dendritic potassium
RT   channels in living neurons.";
RL   J. Biol. Chem. 289:10566-10581(2014).
RN   [75]
RP   PHOSPHORYLATION AT SER-607, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24477962; DOI=10.1002/cne.23551;
RA   King A.N., Manning C.F., Trimmer J.S.;
RT   "A unique ion channel clustering domain on the axon initial segment of
RT   mammalian neurons.";
RL   J. Comp. Neurol. 522:2594-2608(2014).
RN   [76]
RP   FUNCTION, INTERACTION WITH STX1A, AND SUBCELLULAR LOCATION.
RX   PubMed=24928958; DOI=10.1113/jphysiol.2014.276964;
RA   McCord M.C., Kullmann P.H., He K., Hartnett K.A., Horn J.P., Lotan I.,
RA   Aizenman E.;
RT   "Syntaxin-binding domain of Kv2.1 is essential for the expression of
RT   apoptotic K+ currents.";
RL   J. Physiol. (Lond.) 592:3511-3521(2014).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 272-304.
RX   PubMed=18004376; DOI=10.1038/nature06265;
RA   Long S.B., Tao X., Campbell E.B., MacKinnon R.;
RT   "Atomic structure of a voltage-dependent K+ channel in a lipid membrane-
RT   like environment.";
RL   Nature 450:376-382(2007).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 272-304.
RX   PubMed=20360102; DOI=10.1126/science.1185954;
RA   Tao X., Lee A., Limapichat W., Dougherty D.A., MacKinnon R.;
RT   "A gating charge transfer center in voltage sensors.";
RL   Science 328:67-73(2010).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 272-304.
RX   PubMed=23705070; DOI=10.7554/elife.00594;
RA   Banerjee A., Lee A., Campbell E., Mackinnon R.;
RT   "Structure of a pore-blocking toxin in complex with a eukaryotic voltage-
RT   dependent K(+) channel.";
RL   Elife 2:E00594-E00594(2013).
CC   -!- FUNCTION: Voltage-gated potassium channel that mediates transmembrane
CC       potassium transport in excitable membranes, primarily in the brain, but
CC       also in the pancreas and cardiovascular system. Contributes to the
CC       regulation of the action potential (AP) repolarization, duration and
CC       frequency of repetitive AP firing in neurons, muscle cells and
CC       endocrine cells and plays a role in homeostatic attenuation of
CC       electrical excitability throughout the brain (PubMed:10024359,
CC       PubMed:10618149, PubMed:12451110, PubMed:17379638, PubMed:19276663,
CC       PubMed:23878373). Also plays a role in the regulation of exocytosis
CC       independently of its electrical function (PubMed:20484665). Forms
CC       tetrameric potassium-selective channels through which potassium ions
CC       pass in accordance with their electrochemical gradient. The channel
CC       alternates between opened and closed conformations in response to the
CC       voltage difference across the membrane. Homotetrameric channels mediate
CC       a delayed-rectifier voltage-dependent outward potassium current that
CC       display rapid activation and slow inactivation in response to membrane
CC       depolarization (PubMed:12560340, PubMed:1875913, PubMed:2206531,
CC       PubMed:2770868, PubMed:8083226, PubMed:8978827, PubMed:9351973,
CC       PubMed:9565597). Can form functional homotetrameric and
CC       heterotetrameric channels that contain variable proportions of KCNB2;
CC       channel properties depend on the type of alpha subunits that are part
CC       of the channel (PubMed:20202934). Can also form functional
CC       heterotetrameric channels with other alpha subunits that are non-
CC       conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4,
CC       KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally
CC       diverse range of channel complexes (PubMed:8670833, PubMed:8980147,
CC       PubMed:9079713, PubMed:9305895, PubMed:9362476, PubMed:9696692).
CC       Heterotetrameric channel activity formed with KCNS3 show increased
CC       current amplitude with the threshold for action potential activation
CC       shifted towards more negative values in hypoxic-treated pulmonary
CC       artery smooth muscle cells (PubMed:9362476). Channel properties are
CC       also modulated by cytoplasmic ancillary beta subunits such as AMIGO1,
CC       KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the
CC       delayed rectifier potassium channels (PubMed:12954870,
CC       PubMed:19219384). In vivo, membranes probably contain a mixture of
CC       heteromeric potassium channel complexes, making it difficult to assign
CC       currents observed in intact tissues to any particular potassium channel
CC       family member. Major contributor to the slowly inactivating delayed-
CC       rectifier voltage-gated potassium current in neurons of the central
CC       nervous system, sympathetic ganglion neurons, neuroendocrine cells,
CC       pancreatic beta cells, cardiomyocytes and smooth muscle cells
CC       (PubMed:10024359, PubMed:10414968, PubMed:10618149, PubMed:11463864,
CC       PubMed:12127166, PubMed:12403834, PubMed:12451110, PubMed:12621036,
CC       PubMed:12807875, PubMed:12832499, PubMed:12954870, PubMed:15195093,
CC       PubMed:15322114, PubMed:16407566, PubMed:17301173, PubMed:17379638,
CC       PubMed:18167541, PubMed:18463252, PubMed:19276663, PubMed:20484665,
CC       PubMed:21518833, PubMed:22411134, PubMed:23878373, PubMed:9362476,
CC       PubMed:9616203). Mediates the major part of the somatodendritic
CC       delayed-rectifier potassium current in hippocampal and cortical
CC       pyramidal neurons and sympathetic superior cervical ganglion (CGC)
CC       neurons that acts to slow down periods of firing, especially during
CC       high frequency stimulation (PubMed:10618149, PubMed:12451110,
CC       PubMed:16319318, PubMed:16917065, PubMed:17379638, PubMed:19276663,
CC       PubMed:23878373). Plays a role in the induction of long-term
CC       potentiation (LTP) of neuron excitability in the CA3 layer of the
CC       hippocampus (By similarity). Contributes to the regulation of glucose-
CC       induced action potential amplitude and duration in pancreatic beta
CC       cells, hence limiting calcium influx and insulin secretion
CC       (PubMed:11463864). Plays a role in the regulation of resting membrane
CC       potential and contraction in hypoxia-treated pulmonary artery smooth
CC       muscle cells (PubMed:9616203). May contribute to the regulation of the
CC       duration of both the action potential of cardiomyocytes and the heart
CC       ventricular repolarization QT interval (By similarity). Contributes to
CC       the pronounced pro-apoptotic potassium current surge during neuronal
CC       apoptotic cell death in response to oxidative injury (PubMed:12832499,
CC       PubMed:16273079, PubMed:17360683, PubMed:19077057, PubMed:19622611,
CC       PubMed:24928958). May confer neuroprotection in response to
CC       hypoxia/ischemic insults by suppressing pyramidal neurons
CC       hyperexcitability in hippocampal and cortical regions
CC       (PubMed:16319318). Promotes trafficking of KCNG3, KCNH1 and KCNH2 to
CC       the cell surface membrane, presumably by forming heterotetrameric
CC       channels with these subunits (By similarity). Plays a role in the
CC       calcium-dependent recruitment and release of fusion-competent vesicles
CC       from the soma of neurons, neuroendocrine and glucose-induced pancreatic
CC       beta cells by binding key components of the fusion machinery in a pore-
CC       independent manner (PubMed:11463864, PubMed:17301173, PubMed:18167541,
CC       PubMed:20484665, PubMed:22411134). {ECO:0000250|UniProtKB:Q03717,
CC       ECO:0000269|PubMed:10024359, ECO:0000269|PubMed:10414968,
CC       ECO:0000269|PubMed:10618149, ECO:0000269|PubMed:11463864,
CC       ECO:0000269|PubMed:12127166, ECO:0000269|PubMed:12403834,
CC       ECO:0000269|PubMed:12451110, ECO:0000269|PubMed:12560340,
CC       ECO:0000269|PubMed:12621036, ECO:0000269|PubMed:12807875,
CC       ECO:0000269|PubMed:12832499, ECO:0000269|PubMed:12954870,
CC       ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:15322114,
CC       ECO:0000269|PubMed:16273079, ECO:0000269|PubMed:16319318,
CC       ECO:0000269|PubMed:16407566, ECO:0000269|PubMed:16917065,
CC       ECO:0000269|PubMed:17301173, ECO:0000269|PubMed:17360683,
CC       ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:18167541,
CC       ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:1875913,
CC       ECO:0000269|PubMed:19077057, ECO:0000269|PubMed:19219384,
CC       ECO:0000269|PubMed:19276663, ECO:0000269|PubMed:19622611,
CC       ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:20484665,
CC       ECO:0000269|PubMed:21518833, ECO:0000269|PubMed:2206531,
CC       ECO:0000269|PubMed:22411134, ECO:0000269|PubMed:23878373,
CC       ECO:0000269|PubMed:24928958, ECO:0000269|PubMed:2770868,
CC       ECO:0000269|PubMed:8083226, ECO:0000269|PubMed:8670833,
CC       ECO:0000269|PubMed:8978827, ECO:0000269|PubMed:8980147,
CC       ECO:0000269|PubMed:9079713, ECO:0000269|PubMed:9305895,
CC       ECO:0000269|PubMed:9351973, ECO:0000269|PubMed:9362476,
CC       ECO:0000269|PubMed:9565597, ECO:0000269|PubMed:9616203,
CC       ECO:0000269|PubMed:9696692}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000269|PubMed:12065754, ECO:0000269|PubMed:12560340,
CC         ECO:0000269|PubMed:1875913, ECO:0000269|PubMed:2206531,
CC         ECO:0000269|PubMed:2770868, ECO:0000269|PubMed:7576642,
CC         ECO:0000269|PubMed:8083226, ECO:0000269|PubMed:8978827,
CC         ECO:0000269|PubMed:9351973, ECO:0000269|PubMed:9362476,
CC         ECO:0000269|PubMed:9565597};
CC   -!- ACTIVITY REGULATION: Inhibited by 42 nM hanatoxin 1 (HaTx1), a spider
CC       venom toxin of the tarantula G. spatulata (PubMed:7576642). Inhibited
CC       by 100 nM stromatoxin 1 (ScTx1), a spider venom toxin of the tarantula
CC       S. calceata (PubMed:12065754). Modestly sensitive to millimolar levels
CC       of tetraethylammonium (TEA) and 4-aminopyridine (4-AP) (PubMed:1875913,
CC       PubMed:2770868, PubMed:8083226, PubMed:9362476). Completely insensitive
CC       to toxins such as dendrotoxin (DTX) and charybdotoxin (CTX)
CC       (PubMed:9362476). {ECO:0000269|PubMed:12065754,
CC       ECO:0000269|PubMed:1875913, ECO:0000269|PubMed:2770868,
CC       ECO:0000269|PubMed:7576642, ECO:0000269|PubMed:8083226,
CC       ECO:0000269|PubMed:9362476, ECO:0000305|PubMed:10414301,
CC       ECO:0000305|PubMed:15858231}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Note=Homotetrameric channels expressed in xenopus oocytes or in
CC         mammalian non-neuronal cells display delayed-rectifier voltage-
CC         dependent potassium currents which are activated during membrane
CC         depolarization, i.e within a risetime of about 20 msec
CC         (PubMed:2770868). After that, inactivate very slowly, i.e within more
CC         than 5 sec (PubMed:2206531, PubMed:8083226). Their activation
CC         requires low threshold potentials of about -20 to -30 mV, with a
CC         midpoint activation at about 10 mV (PubMed:2206531, PubMed:2770868,
CC         PubMed:8083226). For inactivation, the voltage at half-maximal
CC         amplitude is about -20 mV (PubMed:2206531, PubMed:8083226). The time
CC         constant for recovery after inactivation is about 1.6 sec. Channels
CC         have an unitary conductance of about 8 pS (PubMed:10414301,
CC         PubMed:15858231). The voltage-dependence of activation and
CC         inactivation and other channel characteristics vary depending on the
CC         experimental conditions, the expression system, the presence or
CC         absence of ancillary subunits and post-translational modifications.
CC         {ECO:0000269|PubMed:2206531, ECO:0000269|PubMed:2770868,
CC         ECO:0000269|PubMed:8083226, ECO:0000305|PubMed:10414301,
CC         ECO:0000305|PubMed:15858231};
CC   -!- SUBUNIT: Homotetramer or heterotetramer with KCNB2 (PubMed:20202934).
CC       Heterotetramer with non-conducting channel-forming alpha subunits such
CC       as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and
CC       KCNV1 (PubMed:8670833, PubMed:8980147, PubMed:9079713, PubMed:9305895,
CC       PubMed:9362476, PubMed:9696692). Channel activity is regulated by
CC       association with ancillary beta subunits such as AMIGO1, KCNE1, KCNE2
CC       and KCNE3 (PubMed:12954870, PubMed:19219384). Interacts with KCNV2 (By
CC       similarity). Self-associates (via N-terminus and C-terminus); self-
CC       association is required to regulate trafficking, gating and C-terminal
CC       phosphorylation-dependent modulation of the channel (PubMed:12560340,
CC       PubMed:18463252, PubMed:19690160). Interacts (via C-terminus) with
CC       STX1A (via C-terminus); this decreases the rate of channel activation
CC       and increases the rate of channel inactivation in pancreatic beta
CC       cells, induces also neuronal apoptosis in response to oxidative injury
CC       as well as pore-independent enhancement of exocytosis in neuroendocrine
CC       cells, chromaffin cells, pancreatic beta cells and from the soma of
CC       dorsal root ganglia (DRG) neurons (PubMed:12621036, PubMed:12807875,
CC       PubMed:17301173, PubMed:18167541, PubMed:19077057, PubMed:20484665,
CC       PubMed:22411134, PubMed:24928958). Interacts (via N-terminus) with
CC       SNAP25; this decreases the rate of channel inactivation in pancreatic
CC       beta cells and also increases interaction during neuronal apoptosis in
CC       a N-methyl-D-aspartate receptor (NMDAR)-dependent manner
CC       (PubMed:12403834, PubMed:12807875, PubMed:19077057). Interacts (via N-
CC       terminus and C-terminus) with VAMP2 (via N-terminus); stimulates
CC       channel inactivation rate (PubMed:18542995, PubMed:19077057,
CC       PubMed:19690160). Interacts with CREB1; this promotes channel
CC       acetylation in response to stimulation by incretin hormones
CC       (PubMed:21818121). Interacts (via N-terminus and C-terminus) with
CC       MYL12B (PubMed:24569993). Interacts (via N-terminus) with PIAS3; this
CC       increases the number of functional channels at the cell surface
CC       (PubMed:9565597). Interacts with SUMO1. Interacts (via phosphorylated
CC       form) with PTPRE; this reduces phosphorylation and channel activity in
CC       heterologous cells (By similarity). Interacts (via phosphorylated FFAT
CC       motif) with VAPA and VAPB (By similarity).
CC       {ECO:0000250|UniProtKB:Q03717, ECO:0000250|UniProtKB:Q14721,
CC       ECO:0000269|PubMed:12403834, ECO:0000269|PubMed:12560340,
CC       ECO:0000269|PubMed:12621036, ECO:0000269|PubMed:12807875,
CC       ECO:0000269|PubMed:12954870, ECO:0000269|PubMed:17301173,
CC       ECO:0000269|PubMed:18167541, ECO:0000269|PubMed:18463252,
CC       ECO:0000269|PubMed:18542995, ECO:0000269|PubMed:19077057,
CC       ECO:0000269|PubMed:19219384, ECO:0000269|PubMed:19690160,
CC       ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:20484665,
CC       ECO:0000269|PubMed:21818121, ECO:0000269|PubMed:22411134,
CC       ECO:0000269|PubMed:24569993, ECO:0000269|PubMed:24928958,
CC       ECO:0000269|PubMed:8670833, ECO:0000269|PubMed:8980147,
CC       ECO:0000269|PubMed:9079713, ECO:0000269|PubMed:9305895,
CC       ECO:0000269|PubMed:9362476, ECO:0000269|PubMed:9565597,
CC       ECO:0000269|PubMed:9696692}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10024359,
CC       ECO:0000269|PubMed:10414968, ECO:0000269|PubMed:10618149,
CC       ECO:0000269|PubMed:10719893, ECO:0000269|PubMed:12127166,
CC       ECO:0000269|PubMed:12403834, ECO:0000269|PubMed:12451110,
CC       ECO:0000269|PubMed:12560340, ECO:0000269|PubMed:12615930,
CC       ECO:0000269|PubMed:12621036, ECO:0000269|PubMed:12807875,
CC       ECO:0000269|PubMed:12832499, ECO:0000269|PubMed:12954870,
CC       ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:15322114,
CC       ECO:0000269|PubMed:15855232, ECO:0000269|PubMed:16273079,
CC       ECO:0000269|PubMed:16319318, ECO:0000269|PubMed:16407566,
CC       ECO:0000269|PubMed:16988031, ECO:0000269|PubMed:17192433,
CC       ECO:0000269|PubMed:17301173, ECO:0000269|PubMed:17360683,
CC       ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:17606996,
CC       ECO:0000269|PubMed:17965280, ECO:0000269|PubMed:18167541,
CC       ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:18542995,
CC       ECO:0000269|PubMed:19014551, ECO:0000269|PubMed:19077057,
CC       ECO:0000269|PubMed:19219384, ECO:0000269|PubMed:19276663,
CC       ECO:0000269|PubMed:19690160, ECO:0000269|PubMed:20202934,
CC       ECO:0000269|PubMed:20484665, ECO:0000269|PubMed:21518833,
CC       ECO:0000269|PubMed:21712386, ECO:0000269|PubMed:22411134,
CC       ECO:0000269|PubMed:23878373, ECO:0000269|PubMed:24477962,
CC       ECO:0000269|PubMed:24569993, ECO:0000269|PubMed:24928958,
CC       ECO:0000269|PubMed:7623158, ECO:0000269|PubMed:8083226,
CC       ECO:0000269|PubMed:8463836, ECO:0000269|PubMed:8508921,
CC       ECO:0000269|PubMed:8670833, ECO:0000269|PubMed:8978827,
CC       ECO:0000269|PubMed:8980147, ECO:0000269|PubMed:9079713,
CC       ECO:0000269|PubMed:9305895, ECO:0000269|PubMed:9362476,
CC       ECO:0000269|PubMed:9522360, ECO:0000269|PubMed:9565597,
CC       ECO:0000269|PubMed:9616203, ECO:0000269|PubMed:9696692}. Perikaryon
CC       {ECO:0000269|PubMed:10024359, ECO:0000269|PubMed:10618149,
CC       ECO:0000269|PubMed:10719893, ECO:0000269|PubMed:12954870,
CC       ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:16319318,
CC       ECO:0000269|PubMed:16407566, ECO:0000269|PubMed:16988031,
CC       ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:17965280,
CC       ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:19014551,
CC       ECO:0000269|PubMed:19077057, ECO:0000269|PubMed:1961744,
CC       ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:21518833,
CC       ECO:0000269|PubMed:21712386, ECO:0000269|PubMed:22648171,
CC       ECO:0000269|PubMed:23878373, ECO:0000269|PubMed:24477962,
CC       ECO:0000269|PubMed:24569993, ECO:0000269|PubMed:7623158,
CC       ECO:0000269|PubMed:8463836, ECO:0000269|PubMed:8978827,
CC       ECO:0000269|PubMed:9522360}. Cell projection, dendrite
CC       {ECO:0000269|PubMed:10024359, ECO:0000269|PubMed:10618149,
CC       ECO:0000269|PubMed:10719893, ECO:0000269|PubMed:12954870,
CC       ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:16319318,
CC       ECO:0000269|PubMed:16407566, ECO:0000269|PubMed:17379638,
CC       ECO:0000269|PubMed:17965280, ECO:0000269|PubMed:18463252,
CC       ECO:0000269|PubMed:19014551, ECO:0000269|PubMed:19077057,
CC       ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:21518833,
CC       ECO:0000269|PubMed:21712386, ECO:0000269|PubMed:22648171,
CC       ECO:0000269|PubMed:23878373, ECO:0000269|PubMed:24477962,
CC       ECO:0000269|PubMed:24569993, ECO:0000269|PubMed:7623158,
CC       ECO:0000269|PubMed:8463836, ECO:0000269|PubMed:9522360}. Cell
CC       projection, axon {ECO:0000269|PubMed:19014551,
CC       ECO:0000269|PubMed:22648171, ECO:0000269|PubMed:24477962}. Postsynaptic
CC       cell membrane {ECO:0000269|PubMed:9522360}. Synapse
CC       {ECO:0000269|PubMed:9522360}. Synapse, synaptosome
CC       {ECO:0000269|PubMed:8508921}. Membrane {ECO:0000269|PubMed:8508921};
CC       Multi-pass membrane protein. Lateral cell membrane
CC       {ECO:0000269|PubMed:8978827}. Cell membrane, sarcolemma
CC       {ECO:0000269|PubMed:17965280}. Note=Localizes to high-density
CC       somatodendritic clusters and non-clustered sites on the surface of
CC       neocortical and hippocampal pyramidal neurons in a cortical actin
CC       cytoskeleton-dependent manner (PubMed:10024359, PubMed:10719893,
CC       PubMed:15195093, PubMed:16319318, PubMed:16407566, PubMed:16988031,
CC       PubMed:17379638, PubMed:17606996, PubMed:18463252, PubMed:19014551,
CC       PubMed:1961744, PubMed:22648171, PubMed:23878373, PubMed:24477962,
CC       PubMed:24569993, PubMed:8978827, PubMed:9522360). Localizes also to
CC       high-density clusters in the axon initial segment (AIS), at ankyrin-G-
CC       deficient sites, on the surface of neocortical and hippocampal
CC       pyramidal neurons (PubMed:17379638, PubMed:19014551, PubMed:22648171,
CC       PubMed:24477962). KCNB1-containing AIS clusters localize either in
CC       close apposition to smooth endoplasmic reticulum cisternal organelles
CC       or with GABA-A receptor-containing synapses of hippocampal and cortical
CC       pyramidal neurons, respectively (PubMed:24477962). Localizes to high-
CC       density clusters on the cell surface of atrial and ventricular myocytes
CC       and at the lateral plasma membrane in epithelial cells
CC       (PubMed:17965280, PubMed:8978827). Localizes both to the axial and
CC       transverse tubules (T tubule) and sarcolemma in ventricular myocytes
CC       (PubMed:17965280). Associated with lipid raft domains
CC       (PubMed:15855232). In cortical neurons, apoptotic injuries induce de
CC       novo plasma membrane insertion in a SNARE-dependent manner causing an
CC       apoptotic potassium current surge (PubMed:16273079, PubMed:19077057).
CC       {ECO:0000250|UniProtKB:Q03717, ECO:0000250|UniProtKB:Q14721,
CC       ECO:0000269|PubMed:10024359, ECO:0000269|PubMed:10719893,
CC       ECO:0000269|PubMed:12615930, ECO:0000269|PubMed:12807875,
CC       ECO:0000269|PubMed:12954870, ECO:0000269|PubMed:15195093,
CC       ECO:0000269|PubMed:15855232, ECO:0000269|PubMed:16273079,
CC       ECO:0000269|PubMed:16319318, ECO:0000269|PubMed:16407566,
CC       ECO:0000269|PubMed:16988031, ECO:0000269|PubMed:17301173,
CC       ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:17606996,
CC       ECO:0000269|PubMed:17965280, ECO:0000269|PubMed:18463252,
CC       ECO:0000269|PubMed:19014551, ECO:0000269|PubMed:19077057,
CC       ECO:0000269|PubMed:19219384, ECO:0000269|PubMed:1961744,
CC       ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:21518833,
CC       ECO:0000269|PubMed:22648171, ECO:0000269|PubMed:23878373,
CC       ECO:0000269|PubMed:24477962, ECO:0000269|PubMed:24569993,
CC       ECO:0000269|PubMed:8508921, ECO:0000269|PubMed:8978827,
CC       ECO:0000269|PubMed:9522360}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain (PubMed:12954870,
CC       PubMed:1740690, PubMed:1961744, PubMed:7623158, PubMed:8508921).
CC       Expressed in the hippocampus, cerebral cortex, cerebellum, thalamus,
CC       hypothalamus, olfactory bulb, corpus striatum and medial hebenula
CC       (PubMed:10414301, PubMed:16319318, PubMed:8463836). Expressed in
CC       pancreatic islets (PubMed:12403834). Expressed in heart and skeletal
CC       muscle (PubMed:10414301, PubMed:1740690, PubMed:19219384). Levels
CC       remain constant throughout postnatal development (PubMed:17192433).
CC       Expressed in neocortical pyramidal neurons and inhibitory interneurons
CC       (PubMed:10618149, PubMed:12832499, PubMed:17192433, PubMed:17379638,
CC       PubMed:19014551, PubMed:1961744, PubMed:20202934, PubMed:24477962,
CC       PubMed:9522360). Expressed in the superior cervical ganglion (SCG)
CC       neurons (PubMed:12451110). Expressed in globus pallidus neurons
CC       (PubMed:10414968). Expressed in pancreatic beta cells (PubMed:11463864,
CC       PubMed:22411134). Expressed in cardiomyocytes (PubMed:17965280).
CC       Expressed in arterial smooth muscle, alveolar epithelium and parenchyma
CC       (at protein level) (PubMed:15322114, PubMed:9362476, PubMed:9616203).
CC       Expressed in brain, heart, lung, liver, colon, kidney and adrenal gland
CC       (PubMed:19074135, PubMed:8508921, PubMed:9362476). Expressed in
CC       pyramidal cells of the cerebral cortex, in Purkinje and granule cells
CC       of the cerebellum (PubMed:8463836). Expressed in CA1-CA3 pyramidal
CC       cells, dentate granule cells and interneurons of the hippocampus
CC       (PubMed:10024359, PubMed:7623158). Expressed in pulmonary artery (PA)
CC       smooth muscle cells (PubMed:9362476). {ECO:0000269|PubMed:10024359,
CC       ECO:0000269|PubMed:10414968, ECO:0000269|PubMed:10618149,
CC       ECO:0000269|PubMed:11463864, ECO:0000269|PubMed:12403834,
CC       ECO:0000269|PubMed:12451110, ECO:0000269|PubMed:12832499,
CC       ECO:0000269|PubMed:12954870, ECO:0000269|PubMed:15322114,
CC       ECO:0000269|PubMed:16319318, ECO:0000269|PubMed:17192433,
CC       ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:1740690,
CC       ECO:0000269|PubMed:17965280, ECO:0000269|PubMed:19014551,
CC       ECO:0000269|PubMed:19074135, ECO:0000269|PubMed:19219384,
CC       ECO:0000269|PubMed:1961744, ECO:0000269|PubMed:20202934,
CC       ECO:0000269|PubMed:22411134, ECO:0000269|PubMed:24477962,
CC       ECO:0000269|PubMed:7623158, ECO:0000269|PubMed:8463836,
CC       ECO:0000269|PubMed:8508921, ECO:0000269|PubMed:9362476,
CC       ECO:0000269|PubMed:9522360, ECO:0000269|PubMed:9616203}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryonic brain at 14 dpc, and
CC       thereafter (at protein level) (PubMed:8508921). Expressed in embryonic
CC       brain at 14 dpc, and thereafter (PubMed:8508921).
CC       {ECO:0000269|PubMed:8508921}.
CC   -!- INDUCTION: Down-regulated by angiotensin II in a NFATC3-dependent
CC       manner (PubMed:15322114). {ECO:0000269|PubMed:15322114}.
CC   -!- DOMAIN: The transmembrane segment S4 functions as a voltage-sensor and
CC       is characterized by a series of positively charged amino acids at every
CC       third position. Channel opening and closing is effected by a
CC       conformation change that affects the position and orientation of the
CC       voltage-sensor paddle formed by S3 and S4 within the membrane. A
CC       transmembrane electric field that is positive inside would push the
CC       positively charged S4 segment outwards, thereby opening the pore, while
CC       a field that is negative inside would pull the S4 segment inwards and
CC       close the pore. Changes in the position and orientation of S4 are then
CC       transmitted to the activation gate formed by the inner helix bundle via
CC       the S4-S5 linker region. {ECO:0000250|UniProtKB:P63142}.
CC   -!- DOMAIN: The N-terminal and C-terminal cytoplasmic regions mediate
CC       homooligomerization; self-association is required to regulate
CC       trafficking, gating and C-terminal phosphorylation-dependent modulation
CC       of the channel (PubMed:12560340, PubMed:18463252, PubMed:19690160). The
CC       N-terminal cytoplasmic region is important for interaction with other
CC       channel-forming alpha subunits and with ancillary beta subunits
CC       (PubMed:12954870, PubMed:19219384). The C-terminus is necessary and
CC       sufficient for the restricted localization to, and clustering within,
CC       both in soma and proximal portions of dendrite of neurons and in
CC       lateral membrane of non-neuronal polarized cells (PubMed:10719893,
CC       PubMed:8978827). The C-terminus is both necessary and sufficient as a
CC       mediator of cholinergic and calcium-stimulated modulation of channel
CC       cell membrane clustering localization and activity in hippocampal
CC       neurons (PubMed:16407566). {ECO:0000250|UniProtKB:Q14721,
CC       ECO:0000269|PubMed:10719893, ECO:0000269|PubMed:12560340,
CC       ECO:0000269|PubMed:12954870, ECO:0000269|PubMed:16407566,
CC       ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:19219384,
CC       ECO:0000269|PubMed:19690160, ECO:0000269|PubMed:8978827}.
CC   -!- DOMAIN: The FFAT motif is involved in the interaction with VAPA and
CC       VAPB and its phosphorylation regulates these interactions.
CC       {ECO:0000250|UniProtKB:Q14721}.
CC   -!- PTM: Phosphorylated (PubMed:15195093, PubMed:16319318, PubMed:16407566,
CC       PubMed:18463252, PubMed:8083226). Differential C-terminal
CC       phosphorylation on a subset of serines allows graded activity-dependent
CC       regulation of channel gating in hippocampal neurons (PubMed:16917065,
CC       PubMed:17192433, PubMed:9351973). Ser-607 and Tyr-128 are significant
CC       sites of voltage-gated regulation through
CC       phosphorylation/dephosphorylation activities (PubMed:12615930,
CC       PubMed:17192433). Tyr-128 can be phosphorylated by Src and
CC       dephosphorylated by cytoplasmic form of the phosphatase PTPRE isoform 2
CC       (PubMed:12615930). CDK5-induced Ser-607 phosphorylation increases in
CC       response to acute blockade of neuronal activity (PubMed:21712386).
CC       Phosphorylated on Tyr-128 by Src and on Ser-804 by MAPK14/P38MAPK;
CC       phosphorylations are necessary and sufficient for an increase in plasma
CC       membrane insertion, apoptotic potassium current surge and completion of
CC       the neuronal cell death program (PubMed:17360683, PubMed:19622611).
CC       Phosphorylated on Ser-520, Ser-607, Ser-655 and Ser-804 by CDK5;
CC       phosphorylation is necessary for KCNB1 channel clustering formation
CC       (PubMed:21712386). The Ser-607 phosphorylation state differs between
CC       KCNB1-containing clusters on the proximal and distal portions of the
CC       axon initial segment (AIS) (PubMed:24477962). Highly phosphorylated on
CC       serine residues in the C-terminal cytoplasmic tail in resting neurons
CC       (PubMed:16917065, PubMed:9351973). Phosphorylated in pancreatic beta
CC       cells in response to incretin hormones stimulation in a PKA- and
CC       RPS6KA5/MSK1-dependent signaling pathway, promoting beta cell survival
CC       (PubMed:21818121). Phosphorylation on Ser-567 is reduced during
CC       postnatal development with low levels at P2 and P5; levels then
CC       increase to reach adult levels by P14 (PubMed:17192433).
CC       Phosphorylation on Ser-457, Ser-541, Ser-567, Ser-607, Ser-655 and Ser-
CC       719 as well as the N-terminal Ser-15 are sensitive to calcineurin-
CC       mediated dephosphorylation contributing to the modulation of the
CC       voltage-dependent gating properties (PubMed:16917065, PubMed:17192433).
CC       Dephosphorylation by phosphatase PTPRE isoform 2 confers
CC       neuroprotection by its inhibitory influence on the neuronal apoptotic
CC       potassium current surge in a Zn(2+)-dependent manner (PubMed:19622611).
CC       Dephosphorylated at Ser-607 by protein phosphatase PPP1CA
CC       (PubMed:21712386). Hypoxia-, seizure- or glutamate-induced neuronal
CC       activities promote calcium/calcineurin-dependent dephosphorylation
CC       resulting in a loss of KCNB1-containing clustering and enhanced channel
CC       activity (PubMed:15195093, PubMed:16319318, PubMed:16407566,
CC       PubMed:16917065, PubMed:17192433). In response to brain ischemia, Ser-
CC       567 and Ser-607 are strongly dephosphorylated while Ser-457 and Ser-719
CC       are less dephosphorylated (PubMed:17192433). In response to brain
CC       seizures, phosphorylation levels on Ser-567 and Ser-607 are greatly
CC       reduced (PubMed:17192433). Phosphorylated/dephosphorylated by Src or
CC       FYN tyrosine-protein kinases and tyrosine phosphatase PTPRE in primary
CC       Schwann cells and sciatic nerve tissue (By similarity). Phosphorylation
CC       at Ser-593 of the FFAT motif activates interaction with MOSPD2, VAPA
CC       and VAPB (By similarity). {ECO:0000250|UniProtKB:Q03717,
CC       ECO:0000250|UniProtKB:Q14721, ECO:0000269|PubMed:12615930,
CC       ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:16319318,
CC       ECO:0000269|PubMed:16407566, ECO:0000269|PubMed:16917065,
CC       ECO:0000269|PubMed:17192433, ECO:0000269|PubMed:17360683,
CC       ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:18690023,
CC       ECO:0000269|PubMed:19622611, ECO:0000269|PubMed:21712386,
CC       ECO:0000269|PubMed:21818121, ECO:0000269|PubMed:24477962,
CC       ECO:0000269|PubMed:8083226, ECO:0000269|PubMed:9351973}.
CC   -!- PTM: Acetylated. Acetylation occurs in pancreatic beta cells in
CC       response to stimulation by incretin hormones in a histone
CC       acetyltransferase (HAT)/histone deacetylase (HDAC)-dependent signaling
CC       pathway, promoting beta cell survival (PubMed:21818121).
CC       {ECO:0000269|PubMed:21818121}.
CC   -!- PTM: Sumoylated on Lys-474, preferentially with SUMO1; sumoylation
CC       induces a positive shift in the voltage-dependence of activation and
CC       inhibits channel activity (PubMed:21518833). Sumoylation increases the
CC       frequency of repetitive action potential firing at the cell surface of
CC       hippocampal neurons and decreases its frequency in pancreatic beta
CC       cells (PubMed:21518833). Desumoylated by SENP1 (PubMed:21518833).
CC       {ECO:0000269|PubMed:21518833}.
CC   -!- PTM: Not glycosylated (PubMed:8083226). {ECO:0000269|PubMed:8083226}.
CC   -!- SIMILARITY: Belongs to the potassium channel family. B (Shab) (TC
CC       1.A.1.2) subfamily. Kv2.1/KCNB1 sub-subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA34497.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X16476; CAA34497.1; ALT_INIT; mRNA.
DR   PIR; S05448; CHRTD1.
DR   RefSeq; NP_037318.1; NM_013186.1.
DR   PDB; 2R9R; X-ray; 2.40 A; B/H=272-304.
DR   PDB; 3LNM; X-ray; 2.90 A; B/D=272-304.
DR   PDB; 4JTA; X-ray; 2.50 A; B/Q=274-306.
DR   PDB; 4JTC; X-ray; 2.56 A; B/H=274-306.
DR   PDB; 4JTD; X-ray; 2.54 A; B/H=274-306.
DR   PDB; 8SD3; EM; 2.95 A; A/B/C/D=5-602.
DR   PDB; 8SDA; EM; 3.32 A; A/B/C/D=5-602.
DR   PDBsum; 2R9R; -.
DR   PDBsum; 3LNM; -.
DR   PDBsum; 4JTA; -.
DR   PDBsum; 4JTC; -.
DR   PDBsum; 4JTD; -.
DR   PDBsum; 8SD3; -.
DR   PDBsum; 8SDA; -.
DR   AlphaFoldDB; P15387; -.
DR   EMDB; EMD-40349; -.
DR   EMDB; EMD-40350; -.
DR   SMR; P15387; -.
DR   BioGRID; 247764; 6.
DR   CORUM; P15387; -.
DR   IntAct; P15387; 4.
DR   MINT; P15387; -.
DR   STRING; 10116.ENSRNOP00000065961; -.
DR   BindingDB; P15387; -.
DR   ChEMBL; CHEMBL1075226; -.
DR   GuidetoPHARMACOLOGY; 546; -.
DR   iPTMnet; P15387; -.
DR   PhosphoSitePlus; P15387; -.
DR   PaxDb; 10116-ENSRNOP00000065961; -.
DR   ABCD; P15387; 8 sequenced antibodies.
DR   Ensembl; ENSRNOT00000074023.3; ENSRNOP00000065961.3; ENSRNOG00000046949.3.
DR   Ensembl; ENSRNOT00055007323; ENSRNOP00055005484; ENSRNOG00055004620.
DR   Ensembl; ENSRNOT00060001439; ENSRNOP00060000671; ENSRNOG00060001059.
DR   Ensembl; ENSRNOT00065021296; ENSRNOP00065016456; ENSRNOG00065013004.
DR   GeneID; 25736; -.
DR   KEGG; rno:25736; -.
DR   UCSC; RGD:2954; rat.
DR   AGR; RGD:2954; -.
DR   CTD; 3745; -.
DR   RGD; 2954; Kcnb1.
DR   eggNOG; KOG3713; Eukaryota.
DR   GeneTree; ENSGT00940000154899; -.
DR   HOGENOM; CLU_011722_2_1_1; -.
DR   InParanoid; P15387; -.
DR   OMA; PCKGGVN; -.
DR   OrthoDB; 1478695at2759; -.
DR   PhylomeDB; P15387; -.
DR   Reactome; R-RNO-1296072; Voltage gated Potassium channels.
DR   Reactome; R-RNO-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   PRO; PR:P15387; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   GO; GO:0016324; C:apical plasma membrane; IMP:RGD.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0032590; C:dendrite membrane; IDA:RGD.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0032809; C:neuronal cell body membrane; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:RGD.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:1990635; C:proximal dendrite; IDA:RGD.
DR   GO; GO:0042383; C:sarcolemma; IEA:UniProtKB-SubCell.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:UniProtKB.
DR   GO; GO:0005251; F:delayed rectifier potassium channel activity; IDA:UniProtKB.
DR   GO; GO:0015271; F:outward rectifier potassium channel activity; IMP:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000149; F:SNARE binding; IPI:UniProtKB.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:UniProtKB.
DR   GO; GO:0005249; F:voltage-gated potassium channel activity; IDA:MGI.
DR   GO; GO:0001508; P:action potential; IDA:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProtKB.
DR   GO; GO:0045163; P:clustering of voltage-gated potassium channels; IDA:RGD.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IDA:UniProtKB.
DR   GO; GO:0033605; P:positive regulation of catecholamine secretion; IDA:UniProtKB.
DR   GO; GO:1900454; P:positive regulation of long-term synaptic depression; ISS:UniProtKB.
DR   GO; GO:0010701; P:positive regulation of norepinephrine secretion; IDA:UniProtKB.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:0097623; P:potassium ion export across plasma membrane; IMP:RGD.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006813; P:potassium ion transport; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:InterPro.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098900; P:regulation of action potential; ISS:UniProtKB.
DR   GO; GO:2000671; P:regulation of motor neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0048678; P:response to axon injury; IEP:RGD.
DR   GO; GO:1902065; P:response to L-glutamate; IEP:RGD.
DR   GO; GO:0006904; P:vesicle docking involved in exocytosis; IDA:UniProtKB.
DR   CDD; cd18412; BTB_POZ_KCNB2; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.20.120.350; Voltage-gated potassium channels. Chain C; 1.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR003968; K_chnl_volt-dep_Kv.
DR   InterPro; IPR003973; K_chnl_volt-dep_Kv2.
DR   InterPro; IPR004350; K_chnl_volt-dep_Kv2.1.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR003131; T1-type_BTB.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR11537:SF63; POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY B MEMBER 1; 1.
DR   PANTHER; PTHR11537; VOLTAGE-GATED POTASSIUM CHANNEL; 1.
DR   Pfam; PF02214; BTB_2; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF03521; Kv2channel; 2.
DR   PRINTS; PR00169; KCHANNEL.
DR   PRINTS; PR01514; KV21CHANNEL.
DR   PRINTS; PR01491; KVCHANNEL.
DR   PRINTS; PR01495; SHABCHANNEL.
DR   SMART; SM00225; BTB; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell projection; Exocytosis; Ion channel;
KW   Ion transport; Isopeptide bond; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Potassium; Potassium channel;
KW   Potassium transport; Reference proteome; Synapse; Synaptosome;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation;
KW   Voltage-gated channel.
FT   CHAIN           1..857
FT                   /note="Potassium voltage-gated channel subfamily B member
FT                   1"
FT                   /id="PRO_0000054046"
FT   TOPO_DOM        1..186
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        187..208
FT                   /note="Helical; Name=Segment S1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        209..228
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        229..250
FT                   /note="Helical; Name=Segment S2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        251..259
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        260..280
FT                   /note="Helical; Name=Segment S3"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TOPO_DOM        281..294
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        295..316
FT                   /note="Helical; Voltage-sensor; Name=Segment S4"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TOPO_DOM        317..330
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        331..351
FT                   /note="Helical; Name=Segment S5"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TOPO_DOM        352..364
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   INTRAMEM        365..376
FT                   /note="Helical; Name=Pore helix"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   INTRAMEM        377..384
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TOPO_DOM        385..391
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TRANSMEM        392..420
FT                   /note="Helical; Name=Segment S6"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   TOPO_DOM        421..857
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          59..75
FT                   /note="Self-association"
FT                   /evidence="ECO:0000269|PubMed:18463252,
FT                   ECO:0000269|PubMed:19690160"
FT   REGION          448..481
FT                   /note="Self-association"
FT                   /evidence="ECO:0000269|PubMed:18463252,
FT                   ECO:0000269|PubMed:19690160"
FT   REGION          476..524
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          540..569
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          610..658
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          770..802
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          818..857
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           377..382
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000250|UniProtKB:P63142"
FT   MOTIF           590..596
FT                   /note="FFAT"
FT                   /evidence="ECO:0000250|UniProtKB:Q14721"
FT   COMPBIAS        491..506
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        639..658
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         15
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:18690023"
FT   MOD_RES         128
FT                   /note="Phosphotyrosine; by Src"
FT                   /evidence="ECO:0000269|PubMed:12615930,
FT                   ECO:0000269|PubMed:19622611"
FT   MOD_RES         444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03717"
FT   MOD_RES         457
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17192433, ECO:0000269|PubMed:18690023"
FT   MOD_RES         484
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MOD_RES         519
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         520
FT                   /note="Phosphoserine; by CDK5; in vitro"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:21712386, ECO:0007744|PubMed:22673903"
FT   MOD_RES         541
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:18690023"
FT   MOD_RES         567
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17192433"
FT   MOD_RES         590
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MOD_RES         593
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14721"
FT   MOD_RES         607
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17192433, ECO:0000269|PubMed:18690023,
FT                   ECO:0000269|PubMed:21712386, ECO:0000269|PubMed:24477962"
FT   MOD_RES         655
FT                   /note="Phosphoserine; by CDK5; in vitro"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:18690023, ECO:0000269|PubMed:21712386,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         719
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17192433, ECO:0000269|PubMed:18690023"
FT   MOD_RES         771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MOD_RES         799
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:18690023"
FT   MOD_RES         804
FT                   /note="Phosphoserine; by CDK5, MAPK14; in vitro"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17360683, ECO:0000269|PubMed:18690023,
FT                   ECO:0000269|PubMed:21712386"
FT   MOD_RES         836
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:18690023"
FT   CROSSLNK        474
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:21518833"
FT   MUTAGEN         15
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation. Additive effect on activation and steady-
FT                   state inactivation; when associated with A-457."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         15
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         71
FT                   /note="Q->E: Reduces channel activity."
FT                   /evidence="ECO:0000269|PubMed:12560340"
FT   MUTAGEN         79
FT                   /note="E->D: No effect on channel activity."
FT                   /evidence="ECO:0000269|PubMed:12560340"
FT   MUTAGEN         128
FT                   /note="Y->F: Reduces the increase of plasma membrane
FT                   insertion and apoptotic enhancement of potassium current
FT                   during cell death program. Significant loss of Src-mediated
FT                   phosphorylation and channel activity. Reduces interaction
FT                   with PTPRE. Increases cell viability against apoptotic
FT                   insults. Abolishes the increase of plasma membrane
FT                   insertion and apoptotic enhancement of potassium current
FT                   during cell death program; when associated with D-804."
FT                   /evidence="ECO:0000269|PubMed:12615930,
FT                   ECO:0000269|PubMed:19622611"
FT   MUTAGEN         149
FT                   /note="K->Q: No loss of SUMO-dependent channel activity
FT                   modulation in hippocampal neurons."
FT                   /evidence="ECO:0000269|PubMed:21518833"
FT   MUTAGEN         259
FT                   /note="K->Q: No loss of SUMO-dependent channel activity
FT                   modulation in hippocampal neurons."
FT                   /evidence="ECO:0000269|PubMed:21518833"
FT   MUTAGEN         369
FT                   /note="W->C: Reduces channel activity. Does not inhibit
FT                   membrane plasma subcellular localization, interaction with
FT                   STX1A, pore-independent exocytosis activity and apoptotic
FT                   enhancement of potassium current during cell death program;
FT                   when associated with T-384."
FT                   /evidence="ECO:0000269|PubMed:12451110,
FT                   ECO:0000269|PubMed:12832499, ECO:0000269|PubMed:17301173,
FT                   ECO:0000269|PubMed:17360683, ECO:0000269|PubMed:20202934,
FT                   ECO:0000269|PubMed:20484665, ECO:0000269|PubMed:22411134"
FT   MUTAGEN         384
FT                   /note="Y->T: Reduces channel activity. Does not inhibit
FT                   membrane plasma subcellular localization, interaction with
FT                   STX1A, pore-independent exocytosis activity and apoptotic
FT                   enhancement of potassium current during cell death program;
FT                   when associated with C-369."
FT                   /evidence="ECO:0000269|PubMed:12451110,
FT                   ECO:0000269|PubMed:12832499, ECO:0000269|PubMed:17301173,
FT                   ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:20484665,
FT                   ECO:0000269|PubMed:22411134"
FT   MUTAGEN         444
FT                   /note="S->A: No effect on Src-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:9351973"
FT   MUTAGEN         457
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation. Additive effect on activation and steady-
FT                   state inactivation; when associated with A-15."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         457
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         474
FT                   /note="K->Q: Loss of SUMO-dependent channel activity
FT                   modulation in hippocampal neurons."
FT                   /evidence="ECO:0000269|PubMed:21518833"
FT   MUTAGEN         484
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         484
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         496
FT                   /note="S->A: No effect on Src-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:9351973"
FT   MUTAGEN         541
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         541
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         567
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation. Larger effect on activation and steady-state
FT                   inactivation; when associated with A-607."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         567
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         587
FT                   /note="S->A: Abolishes clustered subcellular distribution
FT                   in neurons."
FT                   /evidence="ECO:0000269|PubMed:10719893"
FT   MUTAGEN         590
FT                   /note="S->A: Abolishes clustered subcellular distribution
FT                   in neurons. Does not affect KCNB1-containing vesicles
FT                   motility."
FT                   /evidence="ECO:0000269|PubMed:10719893,
FT                   ECO:0000269|PubMed:24569993"
FT   MUTAGEN         591
FT                   /note="F->A: Abolishes clustered subcellular distribution
FT                   in neurons."
FT                   /evidence="ECO:0000269|PubMed:10719893"
FT   MUTAGEN         593
FT                   /note="S->A: Abolishes clustered subcellular distribution
FT                   in neurons."
FT                   /evidence="ECO:0000269|PubMed:10719893"
FT   MUTAGEN         607
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation. Larger effect on activation and steady-state
FT                   inactivation; when associated with A-567."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         607
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         655
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         655
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         719
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         719
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         771
FT                   /note="S->A: Shift in voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         771
FT                   /note="S->D: Resists voltage-dependent gating on
FT                   calcineurin-dependent activation and steady-state
FT                   inactivation."
FT                   /evidence="ECO:0000269|PubMed:16917065"
FT   MUTAGEN         804
FT                   /note="S->A: Reduces the increase of plasma membrane
FT                   insertion and apoptotic enhancement of potassium current
FT                   during cell death program. No change in calcineurin-
FT                   dependent regulation of voltage-dependent gating. Abolishes
FT                   the increase of plasma membrane insertion and apoptotic
FT                   enhancement of potassium current during cell death program;
FT                   when associated with F-128."
FT                   /evidence="ECO:0000269|PubMed:16917065,
FT                   ECO:0000269|PubMed:17360683, ECO:0000269|PubMed:19622611"
FT   MUTAGEN         804
FT                   /note="S->D: Does not reduce apoptotic enhancement of
FT                   potassium current during the cell death program."
FT                   /evidence="ECO:0000269|PubMed:17360683"
FT   HELIX           177..180
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           186..208
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   TURN            212..214
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           229..249
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           256..259
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           261..268
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           274..281
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           286..302
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           303..307
FT                   /evidence="ECO:0007829|PDB:4JTA"
FT   HELIX           315..326
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           328..353
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   STRAND          356..358
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           364..375
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   STRAND          381..383
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           388..406
FT                   /evidence="ECO:0007829|PDB:8SD3"
FT   HELIX           409..431
FT                   /evidence="ECO:0007829|PDB:8SD3"
SQ   SEQUENCE   857 AA;  95637 MW;  B3C5B0839AB15FD0 CRC64;
     MPAGMTKHGS RSTSSLPPEP MEIVRSKACS RRVRLNVGGL AHEVLWRTLD RLPRTRLGKL
     RDCNTHDSLL QVCDDYSLED NEYFFDRHPG AFTSILNFYR TGRLHMMEEM CALSFSQELD
     YWGIDEIYLE SCCQARYHQK KEQMNEELKR EAETLREREG EEFDNTCCAE KRKKLWDLLE
     KPNSSVAAKI LAIISIMFIV LSTIALSLNT LPELQSLDEF GQSTDNPQLA HVEAVCIAWF
     TMEYLLRFLS SPKKWKFFKG PLNAIDLLAI LPYYVTIFLT ESNKSVLQFQ NVRRVVQIFR
     IMRILRILKL ARHSTGLQSL GFTLRRSYNE LGLLILFLAM GIMIFSSLVF FAEKDEDDTK
     FKSIPASFWW ATITMTTVGY GDIYPKTLLG KIVGGLCCIA GVLVIALPIP IIVNNFSEFY
     KEQKRQEKAI KRREALERAK RNGSIVSMNM KDAFARSIEM MDIVVEKNGE SIAKKDKVQD
     NHLSPNKWKW TKRALSETSS SKSFETKEQG SPEKARSSSS PQHLNVQQLE DMYSKMAKTQ
     SQPILNTKEM APQSKPPEEL EMSSMPSPVA PLPARTEGVI DMRSMSSIDS FISCATDFPE
     ATRFSHSPLA SLSSKAGSST APEVGWRGAL GASGGRLTET NPIPETSRSG FFVESPRSSM
     KTNNPLKLRA LKVNFVEGDP TPLLPSLGLY HDPLRNRGGA AAAVAGLECA SLLDKPVLSP
     ESSIYTTASA RTPPRSPEKH TAIAFNFEAG VHHYIDTDTD DEGQLLYSVD SSPPKSLHGS
     TSPKFSTGAR TEKNHFESSP LPTSPKFLRP NCVYSSEGLT GKGPGAQEKC KLENHTPPDV
     HMLPGGGAHG STRDQSI
//
